{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:31:44Z","timestamp":1786991504274,"version":"build-2736575974"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003448","name":"General Secretariat for Research and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003448","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jaut.2019.102319","type":"journal-article","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T08:52:53Z","timestamp":1567241573000},"page":"102319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Lambda interferons in immunity and autoimmunity"],"prefix":"10.1016","volume":"104","author":[{"given":"Stelios","family":"Vlachiotis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Andreakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2019.102319_bib1","first-page":"268","article-title":"Virus interference. II. Some properties of interferon","volume":"147","year":"1957","journal-title":"Proc. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.jaut.2019.102319_bib2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1126\/science.149.3681.310","article-title":"Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin","volume":"149","author":"Wheelock","year":"1965","journal-title":"Science"},{"key":"10.1016\/j.jaut.2019.102319_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ni875","article-title":"IFN-\u03bbs mediate antiviral protection through a distinct class II cytokine receptor complex","volume":"4","author":"Kotenko","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ni873","article-title":"IL-28, IL-29 and their class II cytokine receptor IL-28R","volume":"4","author":"Sheppard","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-stimulated genes: a complex web of host defenses","volume":"32","author":"Schneider","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.coi.2011.07.007","article-title":"IFN-\u03bbs","volume":"23","author":"Kotenko","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.it.2015.01.004","article-title":"Interferons and viruses: an evolutionary arms race of molecular interactions","volume":"36","author":"Hoffmann","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","article-title":"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus","volume":"45","author":"Prokunina-Olsson","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jaut.2019.102319_bib9","series-title":"Crossroads between Innate and Adaptive Immunity V","first-page":"1","article-title":"Type III interferons (IFNs): emerging master regulators of immunity","author":"Galani","year":"2015"},{"key":"10.1016\/j.jaut.2019.102319_bib10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.immuni.2017.02.017","article-title":"The IFN-\u03bb-IFN-\u03bbR1-IL-10R\u03b2 complex reveals structural features underlying type III IFN functional plasticity","volume":"46","author":"Mendoza","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2019.102319_bib11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1042\/bj20021935","article-title":"Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3","volume":"370","author":"Dumoutier","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.jaut.2019.102319_bib12","doi-asserted-by":"crossref","first-page":"32269","DOI":"10.1074\/jbc.M404789200","article-title":"Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29\/interferon-\u03bb1: SIMILARITIES WITH TYPE I INTERFERON SIGNALING","volume":"279","author":"Dumoutier","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jaut.2019.102319_bib13","series-title":"HOW CELLS RESPOND TO INTERFERONS","first-page":"40","author":"Stark","year":"1998"},{"key":"10.1016\/j.jaut.2019.102319_bib14","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/hep.26657","article-title":"Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression: Hepatology","volume":"59","author":"Bolen","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2019.102319_bib15","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.immuni.2017.04.025","article-title":"Interferon-\u03bb mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness","volume":"46","author":"Galani","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2019.102319_bib16","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/hep.26653","article-title":"Kinetic differences in the induction of interferon stimulated genes by interferon-\u03b1 and interleukin 28B are altered by infection with hepatitis C virus: Hepatology","volume":"59","author":"Jilg","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2019.102319_bib17","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.4161\/cbt.7.7.6192","article-title":"IFN-\u03b1 and IFN-\u03bb differ in their antiproliferative effects and duration of JAK\/STAT signaling activity","volume":"7","author":"Maher","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jaut.2019.102319_bib18","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1053\/j.gastro.2006.09.052","article-title":"Interferons \u03b1 and \u03bb inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics","volume":"131","author":"Marcello","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2019.102319_bib19","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/ni.3821","article-title":"IFN-\u03bb suppresses intestinal inflammation by non-translational regulation of neutrophil function","volume":"18","author":"Broggi","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib20","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/ni.2915","article-title":"Diverse intracellular pathogens activate type III interferon expression from peroxisomes","volume":"15","author":"Odendall","year":"2014","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib22","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/emmm.201201864","article-title":"Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-\u03bb and elevated secretion of Cxcl10: Usp18 deficiency alters tumour environment","volume":"5","author":"Burkart","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jaut.2019.102319_bib23","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1002\/jcb.24213","article-title":"Interaction of IFN\u03bbR1 with TRAF6 regulates NF-\u03baB activation and IFN\u03bbR1 stability","volume":"113","author":"Xie","year":"2012","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.jaut.2019.102319_bib24","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1007\/s11427-017-9028-6","article-title":"Ran binding protein 9 (RanBPM) binds IFN-\u03bbR1 in the IFN-\u03bb signaling pathway","volume":"60","author":"Zhang","year":"2017","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.jaut.2019.102319_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01232","article-title":"Interferon-\u03bbs: front-line guardians of immunity and homeostasis in the respiratory tract","volume":"8","author":"Andreakos","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.coi.2018.10.007","article-title":"Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control","volume":"56","author":"Andreakos","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib27","unstructured":"H.M. Lazear, B.P. Daniels, A.K. Pinto, A.C. Huang, S.C. Vick, S.E. Doyle, M.G. Jr, R.S. Klein, M.S. Diamond, Interferon-l Restricts West Nile Virus Neuroinvasion by Tightening the Blood-Brain Barrier, (n.d.) vol. 14."},{"key":"10.1016\/j.jaut.2019.102319_bib28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/path.4935","article-title":"Interferon lambda1\/IL-29 and inorganic polyphosphate are novel regulators of neutrophil-driven thromboinflammation: IFN-\u03bb and PolyP in neutrophil thromboinflammation","volume":"243","author":"Chrysanthopoulou","year":"2017","journal-title":"J. Pathol."},{"key":"10.1016\/j.jaut.2019.102319_bib29","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.4049\/jimmunol.180.4.2474","article-title":"An important role for type III interferon (IFN-\/IL-28) in TLR-induced antiviral activity","volume":"180","author":"Ank","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib30","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.4049\/jimmunol.1102038","article-title":"Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells","volume":"189","author":"Yin","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044915","article-title":"Type III interferons, IL-28 and IL-29, are increased in chronic HCV infection and induce myeloid dendritic cell-mediated FoxP3+ regulatory T cells","volume":"7","author":"Dolganiuc","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2019.102319_bib32","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1182\/blood-2005-10-4129","article-title":"Interferon- -treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells","volume":"107","author":"Mennechet","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2019.102319_bib33","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/emmm.201100142","article-title":"IL-28A (IFN-\u03bb2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease: IL-28 promotes Th1 skewing and suppresses asthma","volume":"3","author":"Koltsida","year":"2011","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jaut.2019.102319_bib34","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/eji.200324610","article-title":"Viral infection and Toll-like receptor agonists induce a differential expression of type I and \u03bb interferons in human plasmacytoid and monocyte-derived dendritic cells","volume":"34","author":"Coccia","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib35","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/blood-2009-09-246157","article-title":"IL-4 enhances IFN- 1 (IL-29) production by plasmacytoid DCs via monocyte secretion of IL-1Ra","volume":"115","author":"Megjugorac","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2019.102319_bib36","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1053\/j.gastro.2012.10.034","article-title":"Human type 2 myeloid dendritic cells produce interferon-\u03bb and amplify interferon-\u03b1 in response to hepatitis C virus infection","volume":"144","author":"Zhang","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2019.102319_bib37","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1084\/jem.20092720","article-title":"Mouse CD8\u03b1 + DCs and human BDCA3 + DCs are major producers of IFN-\u03bb in response to poly IC","volume":"207","author":"Lauterbach","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2019.102319_bib38","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/icb.2011.109","article-title":"Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent","volume":"90","author":"Hillyer","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.jaut.2019.102319_bib39","doi-asserted-by":"crossref","first-page":"9608","DOI":"10.1128\/JVI.79.15.9608-9617.2005","article-title":"Gene expression and antiviral activity of alpha\/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells","volume":"79","author":"Osterlund","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.jaut.2019.102319_bib40","doi-asserted-by":"crossref","unstructured":"W. Jordan, J. Eskdale, S. Srinivas, V. Pekarek, D. Kelner, M. Rodia, G. Gallagher, Human interferon lambda-1 (IFN-l1\/IL-29) modulates the Th1\/Th2 response, Genes Immun.. (n.d.) 8.","DOI":"10.1038\/sj.gene.6364382"},{"key":"10.1016\/j.jaut.2019.102319_bib41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1189\/jlb.3VMA0415-144R","article-title":"Endogenously produced TNF-\u03b1 contributes to the expression of CXCL10\/IP-10 in IFN-\u03bb3-activated plasmacytoid dendritic cells","volume":"99","author":"Finotti","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jaut.2019.102319_bib42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cyto.2016.08.005","article-title":"Synergistic production of TNF\u03b1 and IFN\u03b1 by human pDCs incubated with IFN\u03bb3 and IL-3","volume":"86","author":"Finotti","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.jaut.2019.102319_bib43","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/S0016-5085(17)30650-9","article-title":"IL-28-Dependent activation of epithelial STAT1 drives epithelial wound healing in inflammatory bowel disease","volume":"152","author":"Chiriac","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2019.102319_bib44","unstructured":"S. Kasimir, J. Brom, W.K.A. Infektabwehrmechanismen, Effect of Interferon-Alpha on Neutrophil Functions, (n.d.) vol. 8."},{"key":"10.1016\/j.jaut.2019.102319_bib45","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1084\/jem.20140995","article-title":"IFN-\u03bb resolves inflammation via suppression of neutrophil infiltration and IL-1\u03b2 production","volume":"212","author":"Blazek","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2019.102319_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aan5357","article-title":"Type III interferon is a critical regulator of innate antifungal immunity","volume":"2","author":"Espinosa","year":"2017","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib47","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/eji.201847556","article-title":"IL-1\u03b2 activation in response to Staphylococcus aureus lung infection requires inflammasome-dependent and independent mechanisms","volume":"48","author":"Pires","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib48","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1128\/JVI.01773-08","article-title":"Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages","volume":"83","author":"Hou","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.jaut.2019.102319_bib49","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1128\/MCB.01498-14","article-title":"Noncanonical effects of IRF9 in intestinal inflammation: more than type I and type III interferons","volume":"35","author":"Rauch","year":"2015","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.jaut.2019.102319_bib50","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nri3399","article-title":"Neutrophil recruitment and function in health and inflammation","volume":"13","author":"Kolaczkowska","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01661","article-title":"Interferon (IFN)-\u03bb takes the helm: immunomodulatory roles of type III IFNs","volume":"8","author":"Zanoni","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bcp.2019.03.029","article-title":"The many facets of macrophages in rheumatoid arthritis","volume":"165","author":"Siouti","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jaut.2019.102319_bib53","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1128\/JVI.78.8.4363-4369.2004","article-title":"Suppression of the induction of alpha, beta, and gamma interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages","volume":"78","author":"Spann","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.jaut.2019.102319_bib54","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nm1462","article-title":"Role of deficient type III interferon-\u03bb production in asthma exacerbations","volume":"12","author":"Contoli","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.jaut.2019.102319_bib55","article-title":"IFN-\u03bb inhibits drug-resistant HIV infection of macrophages","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib56","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2010-07-298976","article-title":"IL-29 and IFN differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFN receptor expression","volume":"117","author":"Liu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2019.102319_bib57","doi-asserted-by":"crossref","first-page":"E2376","DOI":"10.1073\/pnas.1424241112","article-title":"NK cells require IL-28R for optimal in vivo activity","volume":"112","author":"Souza-Fonseca-Guimaraes","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jaut.2019.102319_bib58","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.4049\/jimmunol.1601430","article-title":"Involvement of NK cells in IL-28B\u2013mediated immunity against influenza virus infection","volume":"199","author":"Wang","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib59","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.10272","article-title":"Concerted action of IFN-\u03b1 and IFN-\u03bb induces local NK cell immunity and halts cancer growth","volume":"7","author":"Lasfar","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaut.2019.102319_bib60","first-page":"1059","article-title":"Antitumor activity of type I and type III interferons in BNL hepatoma model, cancer immunology","volume":"59","author":"Abushahba","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jaut.2019.102319_bib61","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/eji.201444903","article-title":"IFN-\u03bb-mediated IL-12 production in macrophages induces IFN-\u03b3 production in human NK cells: innate immunity","volume":"45","author":"de Groen","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib62","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.humimm.2014.06.016","article-title":"IFNL cytokines do not modulate human or murine NK cell functions","volume":"75","author":"Morrison","year":"2014","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib63","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1089\/jir.2015.0169","article-title":"Immune cell profiling of IFN-\u03bb response shows pDCs express highest level of IFN-\u03bbR1 and are directly responsive via the JAK-STAT pathway","volume":"36","author":"Kelly","year":"2016","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.jaut.2019.102319_bib64","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/gene.2009.72","article-title":"Despite IFN-\u03bb receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines","volume":"10","author":"Witte","year":"2009","journal-title":"Genes Immun."},{"key":"10.1016\/j.jaut.2019.102319_bib65","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1189\/jlb.3A0215-041RR","article-title":"IFN- is able to augment TLR-mediated activation and subsequent function of primary human B cells","volume":"98","author":"de Groen","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jaut.2019.102319_bib66","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1189\/jlb.0212064","article-title":"IFN type I and type II independent enhancement of B cell TLR7 expression by natural killer cells","volume":"92","author":"Sinha","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jaut.2019.102319_bib67","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.bbrc.2006.04.043","article-title":"Novel interferon-\u03bbs induce antiproliferative effects in neuroendocrine tumor cells","volume":"344","author":"Zitzmann","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jaut.2019.102319_bib68","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.4049\/jimmunol.178.8.5086","article-title":"IL-28 elicits antitumor responses against murine fibrosarcoma","volume":"178","author":"Numasaki","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib69","doi-asserted-by":"crossref","first-page":"32269","DOI":"10.1074\/jbc.M404789200","article-title":"Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29\/interferon-\u03bb1: SIMILARITIES WITH TYPE I INTERFERON SIGNALING","volume":"279","author":"Dumoutier","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jaut.2019.102319_bib70","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cyto.2005.04.003","article-title":"Biological activity of interleukins-28 and -29: comparison with type I interferons","volume":"31","author":"Meager","year":"2005","journal-title":"Cytokine"},{"key":"10.1016\/j.jaut.2019.102319_bib71","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1111\/j.1349-7006.2011.02079.x","article-title":"Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer","volume":"102","author":"Fujie","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jaut.2019.102319_bib72","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.lungcan.2012.09.005","article-title":"Potential anti-tumor effect of IFN-?2 (IL-28A) against human lung cancer cells","volume":"78","author":"Tezuka","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jaut.2019.102319_bib73","doi-asserted-by":"crossref","first-page":"G960","DOI":"10.1152\/ajpgi.00126.2005","article-title":"IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression","volume":"289","author":"Brand","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.jaut.2019.102319_bib74","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1365-2184.2008.00558.x","article-title":"Regulation of apoptosis by type III interferons: Regulation of apoptosis by type III interferons","volume":"41","author":"Li","year":"2008","journal-title":"Cell Prolif"},{"key":"10.1016\/j.jaut.2019.102319_bib75","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejca.2009.10.002","article-title":"Interferon-\u03bb induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents","volume":"46","author":"Li","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jaut.2019.102319_bib76","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00430-014-0330-9","article-title":"Interferon lambda 1 expression in cervical cells differs between low-risk and high-risk human papillomavirus-positive women","volume":"203","author":"Cannella","year":"2014","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib77","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/1535-7163.MCT-09-0461","article-title":"Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis","volume":"9","author":"Guenterberg","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jaut.2019.102319_bib78","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1158\/0008-5472.CAN-05-3653","article-title":"Characterization of the mouse IFN-\u03bb ligand-receptor system: IFN-\u03bbs exhibit antitumor activity against B16 melanoma","volume":"66","author":"Lasfar","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.jaut.2019.102319_bib79","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1158\/0008-5472.CAN-09-4658","article-title":"Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer","volume":"70","author":"Wongthida","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.jaut.2019.102319_bib81","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.4049\/jimmunol.176.12.7686","article-title":"Antitumor activity of IFN- in murine tumor models","volume":"176","author":"Sato","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib82","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jaut.2019.102319_bib83","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.gene.2015.09.058","article-title":"The type I interferons: basic concepts and clinical relevance in immune-mediated inflammatory diseases","volume":"576","author":"L\u00f3pez de Padilla","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.jaut.2019.102319_bib84","first-page":"15","article-title":"The pathogenesis of rheumatoid arthritis","author":"McInnes","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2019.102319_bib85","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/08916934.2017.1289181","article-title":"Type-III interferons and rheumatoid arthritis: correlation between interferon lambda 1 (interleukin 29) and antimutated citrullinated vimentin antibody levels","volume":"50","author":"Castillo-Mart\u00ednez","year":"2017","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jaut.2019.102319_bib86","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1620\/tjem.241.89","article-title":"Elevated serum levels of interleukin-29 are associated with disease activity in rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies","volume":"241","author":"Chang","year":"2017","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.jaut.2019.102319_bib87","doi-asserted-by":"crossref","first-page":"R228","DOI":"10.1186\/ar4067","article-title":"Interleukin-29 modulates proinflammatory cytokine production in synovial inflammation of rheumatoid arthritis","volume":"14","author":"Wang","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102319_bib88","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3109\/08916934.2012.730587","article-title":"Serum IFN-\u03bb1 is abnormally elevated in rheumatoid arthritis patients","volume":"46","author":"Wu","year":"2013","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jaut.2019.102319_bib89","doi-asserted-by":"crossref","first-page":"R228","DOI":"10.1186\/ar4067","article-title":"Interleukin-29 modulates proinflammatory cytokine production in synovial inflammation of rheumatoid arthritis","volume":"14","author":"Wang","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102319_bib90","first-page":"1","article-title":"Interleukin-29 enhances synovial inflammation and cartilage degradation in osteoarthritis","volume":"2016","author":"Xu","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.jaut.2019.102319_bib91","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/ar4445","article-title":"Understanding IFN\u03bb in rheumatoid arthritis","volume":"16","author":"de Groen","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102319_bib92","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/art.39621","article-title":"Ocular fluid analysis in children reveals interleukin-29\/interferon-\u03bb1 as a biomarker for juvenile idiopathic arthritis-associated uveitis: levels of IL-29\/IFN\u03bb1 IN JIA-associated uveitis","volume":"68","author":"Haasnoot","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2019.102319_bib93","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1006\/cyto.2001.0934","article-title":"Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE","volume":"15","author":"Chuntharapai","year":"2001","journal-title":"Cytokine"},{"key":"10.1016\/j.jaut.2019.102319_bib94","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.rdc.2009.12.008","article-title":"Interferon-alpha: a therapeutic target in systemic lupus erythematosus","volume":"36","author":"Crow","year":"2010","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.jaut.2019.102319_bib95","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/RHU.0000000000000581","article-title":"Type III interferons in systemic lupus erythematosus: association between interferon \u03bb3, disease activity, and anti-ro\/SSA antibodies","volume":"23","author":"Amezcua-Guerra","year":"2017","journal-title":"J. Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102319_bib96","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2362.2011.02557.x","article-title":"Profiling the expression of interleukin (IL)-28 and IL-28 receptor \u03b1 in systemic lupus erythematosus patients: expression of interleukin (IL)-28 and IL-28 receptor \u03b1","volume":"42","author":"Lin","year":"2012","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.jaut.2019.102319_bib97","doi-asserted-by":"crossref","first-page":"R88","DOI":"10.1186\/ar3363","article-title":"Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity","volume":"13","author":"Wu","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102319_bib98","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/jid.2010.244","article-title":"Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFN\u03bb) in cutaneous lupus erythematosus","volume":"131","author":"Zahn","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.jaut.2019.102319_bib99","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1344-7","article-title":"IFN-\u03bb1 with Th17 axis cytokines and IFN-\u03b1 define different subsets in systemic lupus erythematosus (SLE)","volume":"19","author":"Oke","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102319_bib100","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000170","article-title":"Interferon (IFN)-\u03bb is a potential mediator in lupus nephritis","volume":"3","author":"Zickert","year":"2016","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.jaut.2019.102319_bib101","first-page":"273","article-title":"Sj\u00f6gren\u2019s syndrome, annual review of pathology: mechanisms of disease","volume":"9","author":"Mavragani","year":"2014"},{"key":"10.1016\/j.jaut.2019.102319_bib102","doi-asserted-by":"crossref","first-page":"A305","DOI":"10.1016\/j.autrev.2009.11.004","article-title":"The geoepidemiology of Sj\u00f6gren\u2019s syndrome","volume":"9","author":"Mavragani","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2019.102319_bib103","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaut.2014.01.013","article-title":"Classification criteria of Sj\u00f6gren\u2019s syndrome","volume":"48\u201349","author":"Goules","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102319_bib104","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jaut.2011.12.006","article-title":"Classification criteria for Sjogren's syndrome: a critical review","volume":"39","author":"Baldini","year":"2012","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.102319_bib105","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/art.21006","article-title":"Gene expression profiling of minor salivary glands clearly distinguishes primary Sj\u00f6gren\u2019s syndrome patients from healthy control subjects","volume":"52","author":"Hjelmervik","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102319_bib106","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/gene.2009.20","article-title":"Peripheral blood gene expression profiling in Sj\u00f6gren\u2019s syndrome","volume":"10","author":"Emamian","year":"2009","journal-title":"Genes Immun."},{"key":"10.1016\/j.jaut.2019.102319_bib107","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1073\/pnas.0510837103","article-title":"Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome","volume":"103","author":"Gottenberg","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jaut.2019.102319_bib108","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cei.12865","article-title":"Expression of type III interferons (IFN\u03bbs) and their receptor in Sj\u00f6gren\u2019s syndrome: type III IFNs in SS","volume":"186","author":"Apostolou","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2019.102319_bib109","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/08916934.2015.1054028","article-title":"Interferons and systemic sclerosis: correlation between interferon gamma and interferon-lambda 1 (IL-29)","volume":"48","author":"Dantas","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jaut.2019.102319_bib110","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1056\/NEJMoa021481","article-title":"Endogenous antimicrobial peptides and skin infections in atopic dermatitis","volume":"347","author":"Ong","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2019.102319_bib111","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006245","article-title":"IL-29 is produced by TH17 cells and mediates the cutaneous antiviral competence in psoriasis","volume":"5","author":"Wolk","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jaut.2019.102319_bib112","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.gastro.2017.03.015","article-title":"Activation of epithelial signal transducer and activator of transcription 1 by interleukin 28 controls mucosal healing in mice with colitis and is increased in mucosa of patients with inflammatory bowel disease","volume":"153","author":"Chiriac","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2019.102319_bib113","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jir.2013.0158","article-title":"How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms","volume":"34","author":"Reder","year":"2014","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.jaut.2019.102319_bib114","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jneuroim.2011.08.004","article-title":"IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis","volume":"239","author":"Malhotra","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jaut.2019.102319_bib115","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jneuroim.2012.02.005","article-title":"Analysis of the IL28RA locus as genetic risk factor for multiple sclerosis","volume":"245","author":"Lopez de Lapuente","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jaut.2019.102319_bib116","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1371\/journal.pone.0008720","article-title":"IL-28 supplants requirement for Treg cells in protein s1- mediated protection against murine experimental autoimmune encephalomyelitis (EAE)","volume":"5","author":"Rynda","year":"2010","journal-title":"PLoS One"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841119305219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841119305219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:22:26Z","timestamp":1760257346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841119305219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":114,"alternative-id":["S0896841119305219"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2019.102319","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lambda interferons in immunity and autoimmunity","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2019.102319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102319"}}